Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
National Institutes of Health Clinical Center (CC)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Janssen Research & Development, LLC
Masonic Cancer Center, University of Minnesota
Augusta University
Washington University School of Medicine
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Essen Biotech
Medical College of Wisconsin
University of Alabama at Birmingham
Thomas Jefferson University
Northside Hospital, Inc.
University of Rochester
Mayo Clinic
Indapta Therapeutics, INC.
Institute of Hematology & Blood Diseases Hospital, China
City of Hope Medical Center
The Affiliated People's Hospital of Ningbo University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Melbourne Health
University of Liege